<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">397496656</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180308164522.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">161202e199503  xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1016/S1010-7940(05)80062-4</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)oxford-10.1016/S1010-7940(05)80062-4</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
   <subfield code="a">Comparison of propafenone to atenolol for the prophylaxis of postcardiotomy supraventricular tachyarrhythmias: a prospective trial</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">To compare the efficacy of propafenone to atenolol in the prevention ofsupraventricular tachyarrhythmias (SVT) following cardiac surgery, 207consecutive patients were randomly allocated to receive either propafenone300 mg twice daily (105 patients) or atenolol 50 mg once daily (102patients) orally for 7 days after operation. Double blinding was achievedusing placebos. The end point was the development of a SVT which wassymptomatic, recurrent, or lasting over 2 minutes, or the occurrence ofadverse effects possibly attributable to the drugs. The groups were wellmatched for age, sex, bypass- and cross-clamp times, and other data.Thirteen patients in the propafenone group and 11 in the atenolol groupdeveloped SVT during the first week after operation. (P = 0.89, nonsignificant, chi-squared with Yates' correction). In our study propafenoneand atenolol were of approximately equal efficacy in preventing postcardiotomy SVT. Propafenone may have an advantage in being less negativelyinotropic than atenolol; it could therefore be used in patients with poorleft ventricular function or marginal haemodynamics when a beta blocker iscontraindicated.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">© Springer-Verlag 1995</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">European Journal of Cardio-Thoracic Surgery</subfield>
   <subfield code="d">Elsevier Science B.V.</subfield>
   <subfield code="g">9/3(1995-03), 146-149</subfield>
   <subfield code="x">1010-7940</subfield>
   <subfield code="q">9:3&lt;146</subfield>
   <subfield code="1">1995</subfield>
   <subfield code="2">9</subfield>
   <subfield code="o">ejcts</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1016/S1010-7940(05)80062-4</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1016/S1010-7940(05)80062-4</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">European Journal of Cardio-Thoracic Surgery</subfield>
   <subfield code="d">Elsevier Science B.V</subfield>
   <subfield code="g">9/3(1995-03), 146-149</subfield>
   <subfield code="x">1010-7940</subfield>
   <subfield code="q">9:3&lt;146</subfield>
   <subfield code="1">1995</subfield>
   <subfield code="2">9</subfield>
   <subfield code="o">ejcts</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">CC BY-NC-4.0</subfield>
   <subfield code="u">http://creativecommons.org/licenses/by-nc/4.0</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-oxford</subfield>
  </datafield>
 </record>
</collection>
